Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
New scientist (1971), 2004-07, Vol.183 (2454), p.40-43
Ort / Verlag
London: New Scientist
Erscheinungsjahr
2004
Link zum Volltext
Quelle
Applied Social Sciences Index & Abstracts (ASSIA)
Beschreibungen/Notizen
The discovery of an enzyme, telomerase, that gives cancer cells their everlasting ability to divide, but which is missing from most normal cells, has generated great optimism among researchers into anticancer treatment. However, several major setbacks have been enough to discourage drug companies and convince some researchers that telomerase as a cancer therapy is a dead end, a major blow being the discovery that it takes months for a cancer cell to stop dividing after telomerase activity has ceased. However, researchers investigating deeper into basic telomerase biology have uncovered evidence that this enzyme's role in cancer is a great deal more complex and possibly even more critical than originally thought. There is growing excitement over recent experiments that have uncovered new and more efficient ways of killing cancer cells by exploiting telomerase, one approach involving an anticancer vaccine that trains immune cells to zero in on cells making telomerase. Consequently, some researchers are now optimistic that telomerase may yet emerge as a powerful tool in the fight against cancer. (Quotes from original text)